HCW Biologics

What HCW Biologics does

HCW Biologics Inc. (Nasdaq: HCWB) is a clinical-stage biopharmaceutical company founded in April 2018 by Dr. Hing C. Wong and headquartered in Miramar, Florida (incorporated in Delaware). The company develops fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia using two proprietary platforms — TOBI™ (Tissue factOr-Based fusIon), a tissue-factor scaffold that packs multiple cytokines, single-chain antibodies, and ligands into a single fusion molecule, and TRBC (T-Cell Receptor β Chain Constant Region), which enables construction of multi-chain chimeric polypeptides. The pipeline includes one clinical-stage candidate (HCW9302, an IL-2-based Treg-expander in a first-in-human Phase 1 trial for alopecia areata with planned expansion into atopic dermatitis and organ transplantation), three IND-enabling candidates (HCW11-006, HCW11-040, and HCW11-018b), and two commercial-ready ex vivo reagents (HCW9206 for CAR-T manufacturing and HCW9201 for CIML NK cell manufacturing), each with an FDA Drug Master File on file.

The company has no marketed products and derives revenue primarily from upfront licensing fees, milestone payments, royalties, and equity stakes from out-licensed assets and reagent licensing deals. Reported revenue is highly lumpy: FY2025 was $54,232 (a collapse from $2.6M in FY2024 after the suspension of the Wugen license agreement), while Q1 2026 revenue of $6.5 million was driven largely by a $3.5M upfront cash license fee from Beijing Trimmune Biotech and recognition of an approximately $3.5M co-founder equity stake in the Trimmune joint venture. The company funds operations via small post-IPO follow-on offerings (notably through placement agents Maxim Group LLC and E.F. Hutton & Co.), warrant inducements (with Armistice Capital Master Fund Ltd. as a recurring warrant holder), and a $26.25M non-dilutive real-estate-backed development line of credit executed in April 2023.

HCW Biologics faces material financial and regulatory risks. The company has disclosed substantial doubt about its ability to continue as a going concern in FY2025 and Q1 2026 reporting, has received Nasdaq deficiency notices for both minimum bid price (compliance extension through July 29, 2026) and minimum stockholders' equity (extension through December 31, 2025), and executed a 1-for-40 reverse stock split in April 2025. Offsetting these risks are a proven leadership team (CEO Wong and CSO Rhode previously invented ALT-803 / Anktiva®, FDA-approved in April 2024 following ImmunityBio's acquisition of Altor BioScience), positive preliminary Phase 1 data for HCW9302 in June 2026, a recently formed joint venture in China that advances HCW11-006 toward a 2027 Phase 1 trial, and three IND-enabling candidates progressing toward IND filings in 2027.

Name

HCW Biologics

Legal name

HCW Biologics Inc.

Website

https://hcwbiologics.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune disease, cancer, and senescence-linked indications, leveraging proprietary TOBI™ and TRBC platforms. It has one Phase 1 asset (HCW9302), three IND-enabling candidates, and two commercial-ready cell-therapy reagents.

Ownership category

akta.pro rank

Product category

Immunotherapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medical Laboratories (621511)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Fusion Proteins & Fc-Engineered Biologics (HLAAAAAD)

akta.pro secondary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Fusion immunotherapeutics
• Cytokine-based biologics
• Regulatory T cell expansion
• CAR-T manufacturing reagents
• Senescence-associated disease therapeutics

Headquarters

HQ city

Miramar Beach

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Others

Revenue model

1. Licensing up-front fees and milestone payments: Upfront licensing fees and future milestone payments from out-licensed assets. Closed a $3.5 million upfront cash license fee from Beijing Trimmune Biotech for exclusive worldwide rights to HCW11-006 (March 2026), with additional eligibility for milestone payments and double-digit royalties on future product sales.
2. Equity stakes in licensees: Minority co-founder equity stake in Trimmune joint venture currently valued at approximately $3.5 million, totaling $7.0 million in consideration when combined with the $3.5 million cash license fee.
3. Reagent licensing and royalties (ex vivo): Historical licensing of commercial-ready reagent molecules (HCW9206, HCW9201) used as ex vivo reagents for CAR-T and CIML NK cell production; revenue dropped to $54,232 in FY2025 from $2.6 million in FY2024 due to suspension of the Wugen license agreement. Drug Master File filed with FDA.
4. Future product sales (pre-commercial): Pre-commercial clinical-stage biopharmaceutical with no marketed products; future revenue anticipated from subcutaneous-injection products at the commercialization stage with a focus on cost containment.

Pricing tiers

Go-to-market motion3 records

Core offering

HCW Biologics is a clinical-stage biopharmaceutical company that discovers and develops proprietary fusion immunotherapeutics built on its TOBI™ and TRBC platforms, targeting autoimmune diseases, cancer, and senescence-associated dysplasia. Its commercial offering consists of ex vivo reagents (HCW9206, HCW9201) used by CAR-T and CIML NK cell therapy manufacturers, a Phase 1 clinical-stage IL-2-based Treg expander (HCW9302), and a pipeline of IND-enabling candidates (HCW11-006, HCW11-040, HCW11-018b) developed internally or via licensing partners.

Product overview

HCW Biologics Inc. (Nasdaq: HCWB) is a clinical-stage biopharmaceutical company offering a portfolio of proprietary fusion immunotherapeutics developed from two drug discovery platforms — the TOBI™ (Tissue factOr-Based fusIon) platform and the TRBC (T-Cell Receptor β Chain Constant Region) platform — rather than a single unified product. The portfolio spans commercial-ready ex vivo reagents used in cell-therapy manufacturing (HCW9206 for CAR-T production and HCW9201 for Cytokine-Induced Memory-Like NK cell production), one clinical-stage product candidate currently in a first-in-human Phase 1 trial (HCW9302, an IL-2-based Treg-expander for alopecia areata and other autoimmune indications), and IND-enabling-stage candidates (HCW11-006 licensed to Beijing Trimmune Biotech, HCW11-040 second-generation pembrolizumab-based immune checkpoint inhibitor, and HCW11-018b lead tetravalent BIG-BiTE T-Cell Engager). Together the two platforms underpin all pipeline assets, while commercialization of HCW9206/HCW9201 and clinical advancement of HCW9302/HCW11-018b/HCW11-040 may occur via Company-sponsored programs or corporate partners (e.g., Beijing Trimmune Biotech, WY Biotech, E.F. Hutton & Co.).

Differentiator

Problem solved

Functional benefit

Products and services

• HCW9206 (IL-7/IL-15/IL-21 multi-cytokine ex vivo reagent) Novel multi-cytokine (IL-7/IL-15/IL-21) fusion protein used as a commercial-ready ex vivo reagent to manufacture highly functional CAR-T cells enriched (>50%) for long-lived T memory stem cells (Tscm) for cancer and infectious disease (including HIV) applications. GMP master cell bank and manufacturing process established; Drug Master File filed with the U.S. FDA.
• HCW9201 (IL-12/IL-15/IL-18 CIML NK cell reagent) Fusion molecule comprising IL-12, IL-15, and IL-18 used as a commercial-ready ex vivo reagent to generate Cytokine-Induced Memory-Like (CIML) NK cells for cancer cell therapy manufacturing. GMP master cell bank and manufacturing process established; Drug Master File filed with the U.S. FDA.
• HCW9302 (IL-2-based Treg-expander clinical candidate)

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Medicenna Therapeutics: Developer of engineered IL-2 and IL-4 Superkines (MDNA11, MDNA19) for immuno-oncology and autoimmune disease. Comparable as a clinical-stage cytokine-fusion platform with similar Treg/immune-modulation thesis.
• ImmunityBio: Acquired Altor BioScience (where Dr. Wong invented ALT-803 / Anktiva®) and markets the FDA-approved IL-15 superagonist Anktiva. Closely comparable in cytokine-fusion immuno-oncology approach and overlapping scientific lineage.
• Cue Biopharma: Clinical-stage biotech developing IL-2-based biologics (CUE-101 series) for cancer and autoimmune disease. Directly comparable in modality (engineered cytokine fusion proteins) and target indications (Treg modulation, oncology).
• Alpine Immune Sciences: Developed fusion protein therapeutics (e.g., ALPN-303, davoceticept) targeting autoimmune and inflammatory disease using directed evolution of native immune proteins. Comparable in protein-fusion autoimmune pipeline and Treg-modulating mechanisms.

Emerging players

• Werewolf Therapeutics: Clinical-stage biotech using a PREDATOR platform to engineer tumor-activated cytokine and immune-engager therapeutics. Comparable in cytokine-based fusion immunotherapeutics for oncology and in IND-enabling-stage pipeline status.
• Bolt Biotherapeutics: Develops immune-stimulating antibody conjugates (ISACs) that combine tumor-targeting antibodies with immune agonists, conceptually similar to HCW's fusion-protein approach of co-delivering targeting and immune-stimulatory domains.
• Marker Therapeutics: Clinical-stage cell therapy and immunotherapy company focused on multi-tumor-associated antigen T cells for solid tumors and hematologic malignancies. Comparable as a small-cap clinical-stage immunotherapy developer.
• Inhibrx Biosciences: Clinical-stage biotech developing multi-domain biologic therapeutics (e.g., INBRX-109, INBRX-101) using a single-domain antibody platform to construct fusion proteins. Comparable as a small-cap clinical-stage fusion-protein developer.
• Surface Oncology: Clinical-stage immuno-oncology company developing antibody-based therapeutics targeting the tumor microenvironment. Comparable as a clinical-stage small-cap developing novel immunotherapeutic mechanisms with limited marketed products.

Broad incumbents

• Nektar Therapeutics: Develops PEGylated cytokine therapeutics including NKTR-358 (pegylated IL-2 for Treg expansion in autoimmune disease). Closest direct mechanistic competitor to HCW9302 in Treg-selective IL-2 approaches, though a much larger and broader portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hcw-biologics

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds13 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HCW Biologics